Experimental Drug for Hodgkin's Lymphoma

A new experimental drug for Hodgkin's Lymphoma is showing promise:

"An experimental drug for Hodgkin’s lymphoma, studied at the University of Alabama at Birmingham, showed beneficial effects in stopping tumor growth with moderate side-effects, according to findings published Thursday in the New England Journal of Medicine.

The Phase 1 trial was designed to establish a maximum tolerated dose of brentuximab vedotin (SGN-35), a combination of the monoclonal antibody cAC10 and an antitubulin agent, monomethyl auristatin E (MMAE), developed by Seattle Genetics. Using a dose-escalating protocol, the researchers administered a dose of 0.1 to 3.6 mg per kilogram of body weight.

“Our primary goal was to establish the maximum tolerated dose, one that would not cause adverse side effects of SGN-35,” said Andres Forero-Torres, M.D., an associate scientist in the UAB Comprehensive Cancer Center and a senior author of the study. “In the process, we were pleased to discover that positive responses were observed in 17 of the 45 patients involved in the study, including 11 complete remissions.”"

Read More: http://www.newswise.com/articles/view/570420

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap